Chronic Mountain Sickness, Systemic Vascular Function

Learn more about:
Related Clinical Trial
Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude. Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude Physiological Adaptations to Simulated Intermittent Altitude on Human Health and Performance Iron Status and Cardiopulmonary Physiology Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude. Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude Monitoring of the Cerebral Tissue Oxygenation and Perfusion in the Adapting Climber During Sleep in High Altitude The Psychophysiological Effect of Simulated and Terrestrial Altitude Relationship Between Succinate Dehydrogenase Mutations and High-Altitude Illness Cardio-respiratory Responses During Hypoxic Exercise in Individuals Born Prematurely Gut-microbiota Targeted Nutritional Intervention for Gut Barrier Integrity at High Altitude AZ, MZ, and the Pulmonary System Response to Hypoxia Study of the Effects of Iron Levels on the Lungs at High Altitude Effects of Aircraft Cabin Altitude on Passenger Comfort and Discomfort Three New Ideas to Protect Special Forces From the Stress of High Altitude Breathing Training to Improve Human Performance at High Altitude Oxidative Stress in Hypobaric Hypoxia Safety Evaluation of Aminophylline and Methazolamide Decompression Tables for Diving at Altitude Chronic Mountain Sickness, Systemic Vascular Function Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness Inhaled Budesonide for Altitude Illness Prevention Sickness Evaluation at Altitude With Acetazolamide at Relative Doses Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS) Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE) Drug Combination on Exercise Performance at High Altitude Acclimatization Mechanisms During Ascent to 7500m Prevention of Acute Mountain Sickness by Intermittent Hypoxia Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID) Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent Training in Hypoxia to Prevent Acute Mountain Sickness Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness Inhaled Budesonide and Acute Mountain Sickness Altitude Sickness Prevention and Efficacy of Comparative Treatments Alternative Treatments in Acute Mountain Sickness Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Brief Title

Chronic Mountain Sickness, Systemic Vascular Function

Official Title

Chronic Hypoxemia and Systemic Vascular Function

Brief Summary

      Diseases associated with chronic hypoxemia like chronic obstructive pulmonary disease (COPD)
      or emphysema, represent major medical and socio-economical problems and one of the leading
      cause of morbidity and mortality in the western countries. Recently, is has been shown that
      cardiovascular (CV) diseases contribute highly to the morbidity and mortality of these
      patients. Furthermore, increasing evidence suggest that systemic vascular dysfunction play a
      central role in the mediation of the increased CV risk in patients with COPD. However the
      underlying mechanisms of vascular dysfunction in these patients are incompletely understood.
      Chronic mountain sickness (CMS) is characterized by chronic hypoxemia related at least in
      part to hypoventilation; it affects relatively young adults, and may therefore allow to study
      the effects of chronic hypoxemia. The investigators therefore will assess systemic vascular
      function and test the hypothesis that increased oxidative stress is responsible for this
      dysfunction. Since polyglobulia is a hallmark of chronic hypoxemia and has been suggested to
      affect vascular function, the investigators will test the effects of hemodilution on vascular
      function. Then, the investigators will test the effects of acute oxygen application and 1
      month antioxidative dietary supplement on vascular function.

      Preliminary data suggest that offspring of CMS patients may display pulmonary and systemic
      vascular dysfunction. Antioxidant administration is know to improve vascular function. We
      will test the acute effect of Vitamin C in this setting.

      Finally, since there is considerable inter-individual variability of pulmonary artery
      pressure among CMS patients and the presence of a patent foramen ovale (PFO)is increased in
      clinical conditions associated with pulmonary hypertension and hypoxemia, we will assess the
      prevalence of PFO in healthy high altitude dwellers and in CMS patients and its effects on
      pulmonary artery pressure at rest and during mild exercise.
    



Study Type

Interventional


Primary Outcome

Endothelial Function


Condition

Mountain Sickness

Intervention

Vitamin C and E

Study Arms / Comparison Groups

 Antioxidant
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Dietary Supplement

Estimated Enrollment

50

Start Date

October 2008

Completion Date

December 2021

Primary Completion Date

June 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Patients with Chronic Mountain Sickness and their offspring

        Exclusion Criteria:

          -  Smoking

          -  Lung disease

          -  Arterial Hypertension
      

Gender

All

Ages

10 Years - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

, , 

Location Countries

Bolivia

Location Countries

Bolivia

Administrative Informations


NCT ID

NCT01182792

Organization ID

CMS


Responsible Party

Principal Investigator

Study Sponsor

University of Lausanne Hospitals

Collaborators

 Instituto Boliviano de Biologia de Altura

Study Sponsor

, , 


Verification Date

June 2020